A whole-genome sequencing approach shows early promise over current commercial methods for identifying more patients likely ...

A whole-genome sequencing approach shows early promise over current commercial methods for identifying more patients likely to benefit from PARP inhibitor cancer treatments, according to a study led ...

AstraZeneca has had a setback in its late-stage oncology pipeline, after AKT inhibitor ceralasertib, given in combination with cancer immunotherapy Imfinzi, failed to extend survival in a lung cancer ...

Researchers have identified a new way to reprogram T cells, which are infection and tumor-fighting white blood cells, so that they have a superior memory, thereby making them more effective in killing ...

Novel small molecule inhibitors show promising efficacy in endometrial cancer, with ongoing trials expanding treatment ...

For decades, scientists have investigated the neurokinin-1 receptor (NK1R) as a potential target for treating major ...

Spinal deformities such as scoliosis and kyphosis are among the most serious complications of neurofibromatosis type 1 (NF1), a genetic disorder that affects about one in 3,000 people.

Poly(ADP-ribose) polymerase 1 (PARP-1; ARTD1) inhibitors have been described in a Protheragen Inc. patent as potentially useful for the treatment of cancer, neurodegeneration, cardiovascular disorders ...

A few years ago, I had a patient who affectionately went by the name “Pops.” At 85 years young, he was full of life and juggling multiple health issues alongside prostate cancer, yet determined not to ...